Menopause
Conference Coverage
REPLENISH: Oral estradiol/progesterone slowed bone turnover as it cut VMS
From the Journals
Fezolinetant safe, effective for menopausal vasomotor symptoms
The elective neurokinin 3 receptor antagonist appears to be an effective nonhormone treatment for moderate to severe vasomotor symptoms associated...
Conference Coverage
Beginning estrogen soon after menopause slows atherosclerosis progression
PHOENIX – The study raises a critical question: Is there a time period where getting hormone therapy would be most beneficial for the heart?
From the Journals
Family history of MI may increase CVD mortality after bilateral salpingo-oophorectomy
Removal of the ovaries before the natural age of menopause should be strongly discouraged in women who are not at increased genetic risk for...
Guidelines
New guideline offers recommendations for reproductive health in patients with rheumatic diseases
Among its many recommendations, the guideline strongly advises that women with RMD considering pregnancy switch to pregnancy‐compatible medication...
Sponsored Supplement
Ospemifene, an oral SERM for dyspareunia of menopause: Is it being underutilized?
From the Editor
Progestin-only systemic hormone therapy for menopausal hot flashes
Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively...
Conference Coverage
Menopause hormone therapy found to delay type 2 diabetes
LOS ANGELES – Transdermal delivery of estrogen is the preferred means of administration in women who are obese, who have a risk of DVT, or who...
Conference Coverage
Early postmenopausal risk management leads to ‘optimum health’ for women
PHILADELPHIA – “There’s a major opportunity for us at the onset of menopause to identify risks and initiate preventive strategies.”
Latest News
Bisphosphonates turn 50
ORLANDO – The progress seen in treating postmenopausal women with breast cancer, is not evident in younger, premenopasual women or for other...
Expert Commentary
Does BSO status affect health outcomes for women taking estrogen for menopause?
What do results from the Women’s Health Initiative’s 18-year follow-up study reveal?
Product Review
Product Update: Addyi alcohol ban lifted, fezolinetant trial, outcomes tracker, comfort gown
FDA Removes Alcohol Ban with Addyi
Sprout Pharmaceuticals announced that the US Food and Drug Administration (FDA) has removed...